ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2482 • ACR Convergence 2024

    Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies

    Gerhard Wolff1, Michael E Wechsler2, Jared Silver3, Robert Price4, Rejina Verghis5, Peter Weller6, Peter Merkel7, Thomas Corbridge8 and Paneez Khoury9, 1Clinical Development-Respiratory, GSK, Collegeville, 2Department of Medicine, National Jewish Health, Denver, CO, 3US Medical Affairs-Respiratory, GSK, Durham, 4Biostatistics, GSK, Stevenage, United Kingdom, 5Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, 6Beth Israel Deaconess Medical Center, Department of Medicine, Division of Allergy and Inflammation, Harvard Medical School, Boston, MA, 7Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 8US Value Evidence and Outcomes, GSK, Durham, NC, 9National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose: The 52-week Phase III MIRRA trial demonstrated the safety and efficacy of anti-IL-5 mepolizumab in patients with EGPA. However, longer-term safety data are limited.…
  • Abstract Number: 2497 • ACR Convergence 2024

    Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US

    Muhammad Shamim1, Mazen Allouni2, Haseeb Chaudhary3, Ansaam Daoud4, Loai Dweik5, Hashim Syed6 and Omer Pamuk7, 1University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, 2Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, 3Case Western Reserve University, Westlake, OH, 4Case Western Reserve University/University Hospitals, Akron, OH, 5Cleveland Clinic Akron General Internal Medicine, Akron, OH, 6Case Western/ UH, Cleveland, 7University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH

    Background/Purpose: Hydralazine-induced ANCA-associated vasculitis (HIAAV) is a rare clinical problem.  There is paucity of data regarding clinical features, treatment, and prognosis of hydralazine-induced AAV in…
  • Abstract Number: 2494 • ACR Convergence 2024

    Clinical Characteristics, Predictors for Mortality and Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score on Survival in ANCA-associated Vasculitis in Hong Kong : A Multi-centre Retrospective Cohort Study

    Ka Ho Yeung and Kit Yu Young, Caritas Medical Centre, Hong Kong, Hong Kong

    Background/Purpose: To describe the clinical profile and predictors of mortality of AAV patients in Hong Kong. To compare the accuracy of the latest Five-factor Score…
  • Abstract Number: 2495 • ACR Convergence 2024

    Diffuse Alveolar Hemorrhage in Patient with ANCA-associated Vasculitis AndInterstitial Lung Disease

    Elif Ediboglu1, Samuel Falde1, Misbah Baqir1, Rodrigo Cartin-Ceba2 and Ulrich Specks1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Scottsdale, AZ

    Background/Purpose: The association of interstitial lung disease (ILD) and microscopic polyangiitis (MPA) is increasingly recognized. The implications of ILD as it relates to clinical outcomes…
  • Abstract Number: 0526 • ACR Convergence 2024

    Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study

    Narendra Maharaj1, Dharma rao Uppada2, Naveen Reddy MAREDDY1, Pramod Reddy Pundra1, Anastas Batalov3, Delina Ivanova4, nedyalka staykova5, Asta Baranauskaite6 and Laila Hassan7, 1Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, India, 2Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, 3Medical University of Plovdiv, Medical Faculty, University Hospital "Kaspela", Clinic of Rheumatology, Plovdiv 4000, Bulgaria, Plovdiv, Bulgaria, 4Diagnostic and Consulting Center Aleksandrovska EOOD Sofia 1431, Bulgaria, Sofia, Bulgaria, 5Outpatient Clinic for Specialized Medical Help – Medical Center Kuchuk Paris OOD; Plovdiv 4004, Bulgaria, plovdiv, Bulgaria, 6Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161, Lithuania, Kaunas, Lithuania, 711914 Astoria Blvd. Ste. 330, Houston TX 77089 United States, Houston, TX

    Background/Purpose: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from US-Rituximab (RP) or EU-Rituximab (RMP) to DRL_RI (proposed rituximab biosimilar),…
  • Abstract Number: 2498 • ACR Convergence 2024

    The Methylome Profile of B-cells as a Biomarker of Nephritis in IgA Vasculitis

    Veronica Pulito-Cueto1, Joao Carlos Batista-Liz1, Laura Carmen Terron2, Iván Fernández Rengel3, María Sebastián Mora-Gil4, María Teresa Leonardo5, Ana Peñalba5, Luis Martín-Penagos6, Lara Belmar-Vega7, Cristina Gomez-Fernandez8, Ligia Gabrie-Rodriguez9, Rafael Gálvez Sánchez9, Luis Caminal-Montero10, Ana Turrion Nieves11, Patricia Quiroga Colina12, Esther Vicente-rabaneda13, Belén Sevilla-Pérez14, José Luis Callejas15, Eduardo Andrés-León2, Javier Martin16, Ana María Marquez17, Santos Castañeda13, Ricardo Blanco-Alonso18 and Raquel Lopez-mejias1, 1IDIVAL, Santander, Spain, 2Unidad de Bioinformática, Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, Granada, Spain, 3Bioinformatics Unit, Institute of Parasitology and Biomedicine López-Neyra (IPBLN), CSIC, GENYO, Cen, Granada, Spain, 4Immunopathology Group, IDIVAL, Santander, Spain, 5Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 7Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, 8Division of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 9Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 10Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, 11Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain, 12Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 13Hospital Universitario de La Princesa, Madrid, Spain, 14Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 15Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, 16Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, 17Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, 18Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Nephritis is the main cause of long-term morbidity and mortality in patients with Immunoglobulin-A vasculitis (IgAV) [1, 2]. Unfortunately, sensitive, specific, and non-invasive biomarkers…
  • Abstract Number: 2507 • ACR Convergence 2024

    IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil

    Frederico Pinheiro1, Cristina Orikaza2, Gerson Keppeke3, Emília Sato2 and Alexandre de Souza4, 1Universidade Federal de Sao Paulo - UNIFESP, São Paulo, SP, Brazil, 2Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, 3Universidad Catolica del Norte, São Paulo, Coquimbo, Brazil, 4UNIFESP-EPM, São Paulo, SP, Brazil

    Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic, fibroinflammatory condition affecting almost all organs. It is a rare entity that is continuously being studied worldwide. It…
  • Abstract Number: 2469 • ACR Convergence 2024

    Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis

    Stefano Di Donato1, Vishal Kakkar2, Silvia Bellando-Randone3, Marco Matucci-Cerinic4 and Francesco Del Galdo2, and EUSTAR collaborators, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3University of Florence, Florence, Florence, Italy, 4University San Raffaele Milano, Milano, Milan, Italy

    Background/Purpose: The analysis of the EUSTAR Very Early Diagnosis of Systemic Sclerosis (VEDOSS) study has identified the risk of progression to fulfil 2013 ACR/EULAR classification…
  • Abstract Number: 2502 • ACR Convergence 2024

    Characterization of the Tissue Fibroblast Repertoire in IgG4-Related Ophthalmic Disease

    Eduardo Martin Nares, Gabriela Hernández-Molina, Diana Aguilar-León, Norma Ofelia Uribe-Uribe and Janette Furuzawa-Carballeda, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition characterized by tissue infiltration with IgG4+ plasma cells. Fibrosis in the target organs is one of…
  • Abstract Number: 2464 • ACR Convergence 2024

    Thymic Size Longitudinal Changes on Chest High-resolution Computed Tomography After Autologous Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis

    Grégory Pugnet1, Samia Collot2, Antoine Petermann3, Pauline Lansiaux4, Gwenaelle Larion4, Mathieu Resche-rigon4, Cécile Borel5, Zora Marjanovic6 and Dominique Farge4, 1Toulouse Rangueil University Hospital, Toulouse, France, 2CHU Toulouse, Toulouse, France, 3Clinique Pasteur, Toulouse, France, 4APHP, PAris, France, 5IUCT, Toulouse, France, 6APHP, Toulouse, France

    Background/Purpose: The thymus is a central lymphatic organ responsible for T-cell differentiation and maturation throughout life. The thymus reaches its maximum absolute weight at puberty,…
  • Abstract Number: 0580 • ACR Convergence 2024

    Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis

    Ayantika Talukdar1, Neke Ibeh2, Rohan Machhar2, Mansi Aparnathi3, Sareh Keshavarazi4, Archita Srinath5, Akihiro Nakamura6, Robert Inman7, Proton Rahman8, Igor Jurisica9 and Nigil Haroon10, 1Krembil Research Institute, UHN, Toronto, ON, Canada, 2UHN, Toronto, Canada, 3University Health Network, Toronto, Canada, 4UHN, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Queen's Univesity, Kingston, ON, Canada, 7University Health Network, Toronto, ON, Canada, 8Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, 9Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, 10Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) substantially improve symptoms in Ankylosing Spondylitis (AS), although 40% patients are unresponsive. Identifying biomarkers predictive of TNFi treatment response…
  • Abstract Number: 2511 • ACR Convergence 2024

    Clinical Characteristics and Outcomes of Patients with Clinically Isolated Aortitis

    Mahmut Kaymakci1, Hannah Langenfeld1, Andrew C. Hanson2, Cynthia Crowson1, Melanie Bois1, Hartzell Schaff2, Mohanad Elfishawi3, Matthew Koster1, Cornelia Weyand2 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3University of Minnesota, Minneapolis

    Background/Purpose: Clinically Isolated Aortitis (CIA) is a type of vasculitis affecting the aorta in the absence of systemic vasculitis, rheumatic disease, or infection. Most patients…
  • Abstract Number: 2505 • ACR Convergence 2024

    C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?

    Joao Carlos Batista-Liz1, Vanesa Calvo-Rio2, María Sebastián Mora-Gil3, Ligia Gabrie-Rodriguez4, Rafael Gálvez Sánchez4, Belén Sevilla-Pérez5, José Luis Callejas6, María Teresa Leonardo7, Ana Peñalba7, Javier Narvaez-García8, Luis Martín-Penagos9, Luis Caminal-Montero10, PAZ COLLADO11, Patricia Quiroga Colina12, Esther Vicente-rabaneda13, Esteban Rubio14, Manuel León Luque15, Juan María Blanco-Madrigal16, Eva Galindez-Agirregoikoa17, Santos Castañeda13, Ricardo Blanco-Alonso18, Veronica Pulito-Cueto1 and Raquel Lopez-mejias1, 1IDIVAL, Santander, Spain, 2Valdecilla Hospital, Santander, Cantabria, Spain, 3Immunopathology Group, IDIVAL, Santander, Spain, 4Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 6Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, 7Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 8Hospital Universitario de Bellvitge, Barcelona, Spain, 9Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 10Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, 11Hospital Universitario Severo Ochoa, MADRID, Spain, 12Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 13Hospital Universitario de La Princesa, Madrid, Spain, 14Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, Sevilla, Spain, 15Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Sevilla, Spain, 16Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain., Bilbao, Spain, 17BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 18Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is an inflammatory disease caused by the accumulation of immune complexes of IgA in the walls of small blood vessels…
  • Abstract Number: 2512 • ACR Convergence 2024

    French Multicenter Retrospective Study of Patients with Cocaine- and/or Levamisole-induced Vasculitis and Vasculopathy

    Kevin Chevalier1, François Chasset2, Yoann Zerbib3, Pierre-André Jarrot4, Romain Muller4, Thomas Pires5, Saroumadi Adavane6, Didier Bessis7, Alban Deroux8, Vincent Descamps9, Fanny Domont10, Joëlle Faddoul10, Pierre-Edouard gavand11, Tiphaine Goulenok12, Baptiste Gramont13, Vincent Jachiet14, Gaëlle Leroux15, Matthieu Mahevas16, Julie Merindol17, Loïc Meudec18, Martin Michaud19, Morgane Mourguet20, Héloïse Munos pons21, Yann Nguyen22, Bénédicte Oules23, Thomas Papo24, Jacques Pouchot25, Sébastien Rivière14, Oscar Robert26, Charles ronsin27, Benjamin Rossi28, Delphine Staumont-salle29, Benjamin Terrier30, Nathalie Tieule31, Vollmer Olivier32, Pierre Wolkenstein33, Xavier Puéchal34, Jean-David Bouaziz35, Nicolas Dupin23, Gilles Peytavin36, Jean-Claude Alvarez37, Luc Mouthon38 and Alexis Régent34, 1Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, Paris, France, 2Dermatology, Hôpital Tenon, Paris, France, 3Medical Intensive Care Unit and MP3CV-EA7517, Amiens University Hospital, Amiens, France, Amiens, France, 4Service de Médecine Interne et Immunologie Clinique, Hôpital de La Conception, Marseille, Marseille, France, 5Department of Internal Medicine, CHU Bordeaux, Bordeaux, France., Bordeaux, France, 6Service de Cardiologie, Hôpitaux Saint-Antoine and Tenon, AP-HP, 75012 Paris, France., Paris, France, 7Department of Dermatology and Reference Center for Rare Skin Diseases (MAGEC), Saint-Eloi Hospital, University of Montpellier and INSERM U1058, Montpellier, France., Montpellier, France, 8Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, 9Department of Dermatology, APHP, Bichat Hospital, Paris, France., Paris, France, 10AP-HP. Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose Inflammatoire, F-75013 Paris, France., Paris, France, 11Department of Internal Medicine, Clinique Rhena, Strasbourg, France., Strasbourg, France, 12Assistance Publique Hôpitaux de Paris, Paris, France, 13Internal Medicine Departement, Saint Etienne, Saint Etienne, France, 14Service de médecine interne, AP-HP, Hôpital Saint Antoine, Sorbonne Universite, Paris, France., Paris, France, 15Service de Médecine Interne, AP-HP Hôpital Pitié-Salpêtrière, Paris, France., Paris, France, 16Department of Internal Medicine, APHP, Mondor Hospital, Paris, France., Créteil, France, 17Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, 18Department of Rheumatology, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France., Kremlin Bicêtre, France, 19Department of Internal Medicine, Clinique Saint-Exupery, Toulouse, France., Toulouse, France, 20service de médecine interne CHU Toulouse RANGUEIL, Toulouse, France, 21Department of Internal Medicine, Saint-Etienne University Hospital, Saint-Etienne, France., Saint Etienne, France, 22Université Paris Saclay, Clichy, Ile-de-France, France, 23Dermatology Department, Cochin Hospital, Paris, France., Paris, France, 24Université Paris Cité, Paris, France, 25Service de médecine Interne, Centre National de Référence des syndromes drépanocytaires majeurs de l'adulte, AP-HP, Hôpital Européen Georges Pompidou, Paris, France, Paris, France, 26Groupe Hospitalier Pitié Salpêtrière, Assistance Publique Hopitaux de Paris, Service de Pneumologie et Réanimation Médicale, Paris, France; [email protected]., Paris, France, 27cHD Vendée, La Roche sur Yon, La Roche sur Yon, France, 28Service de médecine interne, maladies infectieuses, Centre hospitalier intercommunal de Robert Ballenger, Aulnay-sous-bois, France., Aulnay-sous-bois, France, 29Service de dermatologie, CHU de Lille, université de Lille, 59000 Lille, France., Lille, France, 30Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 31Rhumatologie, Centre Hospitalier Universitaire Nice, Hôpital Pasteur, Nice, France, 32Department of Immunology and Internal Medicine, Strasbourg University Hospital, Strasbourg, France., Strasbourg, France, 33Department of Dermatology, National Referral Center for Neurofibromatosis, Henri Mondor University Hospital, Assistance Publique- Hôpitaux de Paris, Creteil, France., Créteil, France, 34National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 35Dermatology, Hopital Saint-Louis, Paris, Île-de-France, France., Paris, France, 36Service de Pharmacologie, Université Paris Cité, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France., Paris, France, 37Service de Pharmacologie‑Toxicologie, Hôpital Raymond Poincaré, Groupe Hospitalier Universitaires AP-HP.Paris-Saclay, Garches, 92380, France, Paris, France, 38Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

    Background/Purpose: Levamisole, an imidazothiazole formerly used as an anthelmintic, is also used as a cutting agent to enhance the effects and duration of cocaine. In…
  • Abstract Number: 0556 • ACR Convergence 2024

    Disease Duration, Age and Clinical Features Related to Aortic Valve Sclerosis in Patients with Spondyloarthritis

    Asier García-Alija1, Hye Sang Park1, Patricia Moya1, Ana Laiz1, Carla Marco2, Albert Casals1, Concepcion Pitarch2, Cesar Diaz-Torné1, Berta Paula Magallares3, Ivan Castellvi Barranco1, Susana Fernández-Sánchez1, Andrea García-Guillen2, Jose Luis Tandaipan1, Helena Codes-Mendez1, Guillem Verdaguer1, Luis Sainz1 and Hèctor Corominas1, 1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Hospital Dos de Maig, Barcelona, Spain, 3Dept of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, ES, Barcelona, Spain

    Background/Purpose: Valve degeneration is prevalent in Spondylarthritis (SpA) patients according to descriptive studies, but it is also common in general population. Disease burden may be…
  • « Previous Page
  • 1
  • …
  • 214
  • 215
  • 216
  • 217
  • 218
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology